462 related articles for article (PubMed ID: 19046739)
1. Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery.
Fabbrini E; Klein S
Clin Cornerstone; 2008; 9(1):41-8; discussion 49-51. PubMed ID: 19046739
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
4. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Caterson ID; Finer N
Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
[TBL] [Abstract][Full Text] [Related]
5. Obesity Management in Adults: A Review.
Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
[TBL] [Abstract][Full Text] [Related]
6. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.
Cannon CP; Kumar A
Clin Cornerstone; 2009; 9(4):55-68; discussion 69-71. PubMed ID: 19789064
[TBL] [Abstract][Full Text] [Related]
7. The new role of pharmacotherapy for weight reduction in obesity.
Fernstrom MH; Fernstrom JD
Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
[TBL] [Abstract][Full Text] [Related]
8. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Leung WY; Thomas GN; Chan JC; Tomlinson B
Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
10. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
11. Treatment of obesity in 2015.
Shukla AP; Buniak WI; Aronne LJ
J Cardiopulm Rehabil Prev; 2015; 35(2):81-92. PubMed ID: 25714749
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz E; Martín Folgueras T
Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
[TBL] [Abstract][Full Text] [Related]
13. Office-based strategies for the management of obesity.
Rao G
Am Fam Physician; 2010 Jun; 81(12):1449-56 ; quiz 1429. PubMed ID: 20540483
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for modifying cardiometabolic risk factors.
Aronne LJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
[TBL] [Abstract][Full Text] [Related]
15. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
16. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
Hemo B; Endevelt R; Porath A; Stampfer MJ; Shai I
Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
[TBL] [Abstract][Full Text] [Related]
17. Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese.
Frost G; Lyons F; Bovill-Taylor C; Carter L; Stuttard J; Dornhorst A
J Hum Nutr Diet; 2002 Aug; 15(4):287-95; quiz 297-9. PubMed ID: 12153502
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
19. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
20. Long-term pharmacotherapy for obesity.
Klein S
Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
